Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Chem Biol Interact ; 280: 117-127, 2018 Jan 25.
Artículo en Inglés | MEDLINE | ID: mdl-29225136

RESUMEN

Several quinazoline derivatives have been found to possess a broad spectrum of biological activities. Previously our research group has synthesized and studied the anti-proliferative effects of N-Decyl-N-(2-Methyl-4-Quinazolinyl) Amine (DMQA). The current study evaluated the cytotoxic and apoptotic properties of DMQA in THP-1 cells. The cytotoxic potential of DMQA was assessed using MTT assay on a panel of cancer cell lines which include HeLa, Mia PaCa-2, A 375, B16-F10, A 549,A 431, U937, THP-1, HL-60 and peripheral blood mononuclear cells (PBMC's). Preliminary data revealed that the highest cytotoxic activity was against THP-1 leukemia cell line (IC50=0.66 µg/ml). The apoptotic properties of DMQA on THP-1 cells were characterized by change in nuclear morphology, DNA fragmentation, reduction of pro-caspases-3, 9, Bax/Bcl-2 levels, cleavage of poly (ADP-ribose) polymerase and cytosolic release of cytochrome c. Further investigation revealed a sub-G1 peak, phosphatidyl serine exposure and loss of mitochondrial membrane potential (MMP) in THP-1 cells. The role of caspases was crucial and was demonstrated by the inhibitors Z-VAD-FMK and Z-DEVD-FMK. Moreover DMQA was markedly less effective in inhibiting the growth of normal cells (PBMC's, IC50 =62.17 µg/ml). Based on the results we suggest that DMQA induced apoptosis via intrinsic pathway and could be a promising anticancer agent.


Asunto(s)
Apoptosis/efectos de los fármacos , Caspasas/metabolismo , Quinazolinas/farmacología , Clorometilcetonas de Aminoácidos/farmacología , Animales , Antineoplásicos/química , Antineoplásicos/farmacología , Caspasas/química , Proliferación Celular/efectos de los fármacos , Células Cultivadas , Fragmentación del ADN/efectos de los fármacos , Puntos de Control de la Fase G1 del Ciclo Celular/efectos de los fármacos , Células HL-60 , Células HeLa , Humanos , Leucemia/metabolismo , Leucemia/patología , Leucocitos Mononucleares/citología , Leucocitos Mononucleares/efectos de los fármacos , Leucocitos Mononucleares/metabolismo , Potencial de la Membrana Mitocondrial/efectos de los fármacos , Ratones , Poli(ADP-Ribosa) Polimerasas/metabolismo , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Quinazolinas/química , Proteína X Asociada a bcl-2/metabolismo
2.
Eur J Med Chem ; 46(8): 3462-8, 2011 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-21632155

RESUMEN

A series of novel alkyltriazole tagged pyrido[2,3-d]pyrimidine derivatives 5 and 6 was prepared starting from 2,3-active functional pyridine 1via cyclization, propargylation followed by reaction with alkyl or perfluoroalkyl azides under Sharpless conditions. All the compounds 5 and 6 were screened for anticancer activity against three cancer cell lines such as U(937), THP-1 and Colo205. The promising compounds 5b and 5e have been identified.


Asunto(s)
Antineoplásicos/síntesis química , Azidas/química , Supervivencia Celular/efectos de los fármacos , Pirimidinas/síntesis química , Triazoles/química , Alquilación , Antineoplásicos/farmacología , Línea Celular Tumoral , Neoplasias Colorrectales/tratamiento farmacológico , Neoplasias Colorrectales/patología , Ciclización , Ensayos de Selección de Medicamentos Antitumorales , Humanos , Concentración 50 Inhibidora , Leucemia Monocítica Aguda/tratamiento farmacológico , Leucemia Monocítica Aguda/patología , Linfoma/tratamiento farmacológico , Linfoma/patología , Pirimidinas/farmacología , Relación Estructura-Actividad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA